je.st
news
'Suicidal ideation' leads to end of Amgen-AstraZeneca drug partnership
2015-05-26 23:58:21| Biotech - Topix.net
Amgen has pulled out of a co-development deal it had with AstraZeneca for an experimental psoriasis drug, which was in the late stages of clinical development, after observing "suicidal ideation" in some patients during clinical testing of the new drug candidate. Dr. Sean E. Harper , executive vice president of research and development at Amgen, said the company believed the likelihood of the drug being required to carry warning labels of suicide risk would limit the potential market for the treatment.
Tags: end
drug
leads
partnership
Category:Biotechnology and Pharmaceuticals
Latest from this category |
All news |
||
|
|||